English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

#e reasons for the lack of access to essential healthcare policies and medicines are manifold, but in many cases the high prices of drugs create a barrier to needed treatments in developing countries.1 #ese prohibitive drug prices are often the result of corporations in industrialized nations holding patents on the technology to produce their recently discovered medicine. Strong intellectual property rights were developed for pharmaceutical companies who invested in the creation of new medicines to receive the maximum pro$t from their innovation. However, the monopolization of these medicines’ production gives the corporation the ability to sell their product at a high cost, often unreachable for poor countries to a"ord. Governments in these developing countries have attempted to bring down the prices of medicines yet been blocked by industrialized countries who formulated the World Trade Organization Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement to set strong standards for the protection of intellectual property, 1 Ellen Hoen, “TRIPS, Pharmaceutical Patents and Access to Essential Medicines: Seattle, Doha and Beyond,” Chicago Journal for International Law, Vol. 3, no 1 (Spring 2002).

The Human Rights Perspective Behind Patent Laws